-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 9, the NMPA official website released the latest batch of drug approval information, and Hunan Nanfang Sheng Pharmaceutical’s omeprazole enteric-coated tablets were approved and passed the consistency evaluation
.
Omeprazole is the TOP1 product for the treatment of peptic ulcers.
Affected by the epidemic and the price reduction of centralized procurement, the sales of this product in Chinese public medical institutions have declined in 2020, but it has maintained a positive growth trend in physical pharmacies in Chinese cities.
.
Figure 1: The status of the products reviewed by Fangsheng Pharmaceutical this time.
Source: NMPA official website.
Figure 2: The sales of omeprazole in the retail market (unit: 10,000 yuan).
Source: China city physical pharmacy database.
At the physical pharmacy terminal in Chinese cities , omeprazole is the only peptic ulcer drug with sales exceeding 1 billion yuan.
Among the TOP5 varieties in 2020, only omeprazole will maintain a positive growth trend.
Rabeprazole and estrogen The sales of omeprazole (esomeprazole), pantoprazole, and lansoprazole all declined to varying degrees
.
Judging from the over-assessment, omeprazole has passed assessment enterprises have five, have been included in the third batch of national centralized procurement catalog; Omeprazole Sodium for Injection is over 13 enterprises assessment; and Austria Meprazole enteric-coated tablets, Shandong New Times Pharmaceutical won the first review earlier this time, Hunan Nansheng Pharmaceutical is the second
.
Table 1: Consistency evaluation status of Hunan Nansheng Pharmaceutical has been reviewed and under review Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Hunan Nansheng Pharmaceutical has reviewed/deemedly reviewed 4 products , Involving two major categories of digestive system and metabolic drugs and cardiovascular system drugs
.
In addition, the supplementary application for the consistency evaluation of the systemic anti-infective drug cefixime tablets is under review and approval.
At present, only two companies have reviewed it, and Hunan Nanfang Sheng Pharmaceutical is expected to hit the third one
.
Source: NMPA official website, Minet.
com database.
The review data statistics are as of September 8.
If there are any errors or omissions, please correct me
.
.
Omeprazole is the TOP1 product for the treatment of peptic ulcers.
Affected by the epidemic and the price reduction of centralized procurement, the sales of this product in Chinese public medical institutions have declined in 2020, but it has maintained a positive growth trend in physical pharmacies in Chinese cities.
.
Figure 1: The status of the products reviewed by Fangsheng Pharmaceutical this time.
Source: NMPA official website.
Figure 2: The sales of omeprazole in the retail market (unit: 10,000 yuan).
Source: China city physical pharmacy database.
At the physical pharmacy terminal in Chinese cities , omeprazole is the only peptic ulcer drug with sales exceeding 1 billion yuan.
Among the TOP5 varieties in 2020, only omeprazole will maintain a positive growth trend.
Rabeprazole and estrogen The sales of omeprazole (esomeprazole), pantoprazole, and lansoprazole all declined to varying degrees
.
Judging from the over-assessment, omeprazole has passed assessment enterprises have five, have been included in the third batch of national centralized procurement catalog; Omeprazole Sodium for Injection is over 13 enterprises assessment; and Austria Meprazole enteric-coated tablets, Shandong New Times Pharmaceutical won the first review earlier this time, Hunan Nansheng Pharmaceutical is the second
.
Table 1: Consistency evaluation status of Hunan Nansheng Pharmaceutical has been reviewed and under review Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Hunan Nansheng Pharmaceutical has reviewed/deemedly reviewed 4 products , Involving two major categories of digestive system and metabolic drugs and cardiovascular system drugs
.
In addition, the supplementary application for the consistency evaluation of the systemic anti-infective drug cefixime tablets is under review and approval.
At present, only two companies have reviewed it, and Hunan Nanfang Sheng Pharmaceutical is expected to hit the third one
.
Source: NMPA official website, Minet.
com database.
The review data statistics are as of September 8.
If there are any errors or omissions, please correct me
.
